ALLARITY THERAPEUTICS INC (ALLR) Stock News

USA - Nasdaq - NASDAQ:ALLR - US0167445008 - Common Stock

1.33 USD

+0.08 (+6.4%)

Last: 11/28/2025, 8:12:25 PM

1.301 USD

-0.03 (-2.18%)

After Hours: 11/28/2025, 8:12:25 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ALLR Latest News, Press Relases and Analysis

All

Press Releases

16 days ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

16 days ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

2 months ago - By: Benzinga - Mentions: CCCC MBX HSDT ADVM ...

12 Health Care Stocks Moving In Monday's Intraday Session

2 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

2 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

3 months ago - By: Stocktwits

News Image

Why Did Allarity Therapeutics Stock Double In Value Today?

2 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

2 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

3 months ago - By: Zacks Investment Research - Mentions: BSX

Are Medical Stocks Lagging Boston Scientific (BSX) This Year?

3 months ago - By: Benzinga - Mentions: NBY BOLT EPIX RMTI ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

3 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

3 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

4 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

4 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

5 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

5 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

5 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

5 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

5 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic

5 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic

5 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

5 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

6 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Changes to Board of Directors

6 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Changes to Board of Directors

6 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action

6 months ago - By: Allarity Therapeutics, Inc.

Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action